HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Seeking the mechanism(s) of action for corticosteroids in HELLP syndrome: SMASH study.

AbstractINTRODUCTION:
Administration of dexamethasone to the hemolysis, elevated liver enzymes, and low platelet count (HELLP) syndrome patients (10 mg intravenously [IV] every 12 hours) shortens the disease course and reduces maternal morbidity in patients treated at the University of Mississippi Medical Center (UMMC), associated with this severe form of preeclampsia. However, the pathophysiological mechanisms involved with this intervention remain unclear.
OBJECTIVE:
We sought to investigate the potential role of IV dexamethasone to restore the imbalance among antiangiogenic and inflammatory factors known to be significantly elevated in women with HELLP syndrome.
STUDY DESIGN:
This was a single-center prospective study of women diagnosed with HELLP syndrome who were treated for IV dexamethasone at UMMC. Blood was drawn prior to dexamethasone administration and again 12 and 24 hours after the initial dexamethasone administration. Enzyme-linked immune assays were used to measure circulating inflammatory cytokines and antiangiogenic factors. A repeated-measures analysis of variance was used to analyze the data collected before, after, and during dexamethasone administration.
RESULTS:
Seventeen women with HELLP syndrome were enrolled in this study. Dexamethasone significantly decreased evidence of hemolysis (P = .002) and liver enzymes (P = .003), and significantly increased platelets (P = .0001) within 24 hours of administration. Circulating interleukin-6 levels after 24 hours were decreased (P < .001); soluble fms-like tyrosine kinase-1 and soluble endoglin were also significantly decreased by 24 hours after dexamethasone administration (P < .002 and P < .004, respectively). There were no significant differences in circulating levels of placental growth factor (P = .886) due to dexamethasone administration. Angiotensin II receptor autoantibody levels were unchanged by dexamethasone administration.
CONCLUSION:
We conclude that 1 important mechanism of dexamethasone administration is to blunt the release of both antiangiogenic and inflammatory factors suggested to play role in the pathophysiology of HELLP syndrome.
AuthorsKedra Wallace, James N Martin Jr, Kiran Tam Tam, Gerd Wallukat, Ralf Dechend, Babbette Lamarca, Michelle Y Owens
JournalAmerican journal of obstetrics and gynecology (Am J Obstet Gynecol) Vol. 208 Issue 5 Pg. 380.e1-8 (May 2013) ISSN: 1097-6868 [Electronic] United States
PMID23380266 (Publication Type: Clinical Trial, Journal Article)
CopyrightCopyright © 2013 Mosby, Inc. All rights reserved.
Chemical References
  • Angiogenesis Inhibitors
  • Biomarkers
  • Glucocorticoids
  • Interleukin-6
  • Tumor Necrosis Factor-alpha
  • Dexamethasone
Topics
  • Adolescent
  • Adult
  • Analysis of Variance
  • Angiogenesis Inhibitors (blood)
  • Biomarkers (blood)
  • Blood Platelets (drug effects)
  • Dexamethasone (pharmacology, therapeutic use)
  • Drug Administration Schedule
  • Enzyme-Linked Immunosorbent Assay
  • Female
  • Glucocorticoids (pharmacology, therapeutic use)
  • HELLP Syndrome (blood, drug therapy)
  • Hemolysis (drug effects)
  • Humans
  • Injections, Intravenous
  • Interleukin-6 (blood)
  • Liver (drug effects, enzymology)
  • Pregnancy
  • Prospective Studies
  • Treatment Outcome
  • Tumor Necrosis Factor-alpha (blood)
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: